news
Kenai Therapeutics Appoints Blake Arnold, CFA, as Chief Business Officer
FEBRUARY 24, 2026
JANUARY 5, 2026
Kenai Therapeutics Receives $8M Grant from California Institute for Regenerative Medicine (CIRM) to Advance RNDP-001 for Treatment of Idiopathic Parkinson's Disease
DECEMBER 15, 2025
Kenai Therapeutics Announces First Patient Dosed in Phase 1 REPLACE™ Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson’s Disease
FEBRUARY 12, 2025
Kenai Therapeutics Establishes Research Facility at Lilly Gateway Labs
NOVEMBER 14, 2024
Kenai Therapeutics Establishes Patient Advisory Board
OCTOBER 23, 2024
Kenai Therapeutics Announces the Appointment of Dr. Derek Hei as Chief Technology Officer
FEBRUARY 29, 2024
Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases
Kenai Therapeutics Appoints Allen Waldrop to Board of Directors
MARCH 12, 2026